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1. Introduction 
Atrial fibrillation (AF), the most commonly encountered arrhythmia in clinical practice, is 
associated with significant morbidity and mortality. Of great significance are heart failure 
and stroke.1 With increased incidence and prevalence of AF, it represents a growing clinical 
and economic burden. AF is also a progressive disease secondary to continuous structural 
remodeling of the atria because of AF itself, to changes associated with ageing and to 
deterioration of underlying heart disease. Current management aims at preventing the 
recurrence of AF and its consequences and includes risk assessment and prevention of 
stroke, control of ventricular rate and rhythm control therapies including antiarrhythmic 
drugs and catheter or surgical ablation. 
2. Classification 
The nomenclature used to classify AF has been diverse. AF can be acute (first detectable episode 
whether symptomatic or not) or chronic (paroxysmal, persistent, and long-standing persistent), 
or finally permanent. According to a consensus document2, paroxysmal AF is defined as at least 
two episodes that terminate spontaneously within 7 days. Persistent AF is defined as lasting 
more than 7 days, or lasting less than 7 days but necessitating pharmacologic or electrical cardio 
version. Permanent AF is defined as lasting more than 1 year. 
These definitions apply only to episodes that last at least 30 seconds and have no identifiable 
reversible cause, such as acute pulmonary disease or hyperthyroidism. Both paroxysmal 
and persistent atrial fibrillations are potentially recurrent arrhythmias. Paroxysmal atrial 
fibrillation may become persistent with time; and both paroxysmal and persistent AF may 
become permanent. 
The term “lone atrial fibrillation” refers to AF in young people (aged under 60) in whom no 
apparent cause can be identified. 
3. Pathophysiology 
The exact mechanisms by which cardiovascular risk factors predispose to AF are not 
understood fully but are under intense investigation. Catecholamine excess, hemodynamic 
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stress, atrial ischemia, atrial inflammation, metabolic stress, and neurohumoral cascade 
activation are all purported to promote AF. Although the precise mechanisms that cause AF 
are incompletely understood, AF appears to require both an initiating event and a 
permissive atrial substrate. AF results from multiple re-entrant electrical wavelets that move 
randomly around the atria. These wavelets are initiated by electrical triggers, commonly 
located in the myocardial sleeves extending from the left atrium to the proximal 5-6 cm 
portions of the pulmonary veins3. Other sites in the left and right atria and in the proximal 
superior vena cava may less frequently trigger atrial fibrillation4, 5. Once triggered, the atrial 
tissue harbors these wavelets and promotes re-entry, thus facilitating persistence of the 
arrhythmia. A period of AF initially induces electrophysiological changes (“electrical 
remodeling”) followed by structural changes (“structural remodeling”), which facilitate its 
persistence- hence the phrase "atrial fibrillation begets atrial fibrillation"6, 7. 
 
Common causes of Atrial Fibrillation 
Cardiovascular 
 
• Rheumatic heart disease 
• Hypertension 
• Coronary artery disease 
• Congestive heart failure 
• Non rheumatic valvular heart disease   
• Sick sinus syndrome 
• Wolf-Parkinson-white syndrome 
• Pericarditis 
• Endocarditis 
• Cardiomyopathy 
• Congenital heart disease 
Non-cardiovasular 
 
• Endocrine disorders 
(e.g.,Hyperthyroidism) 
• Respiratory causes (e.g., pneumonia, 
pulmonary thromboembolism) 
• Alcohol and drug use 
 
Atrial fibrillation with poor ventricular rate control can cause electrical and structural 
remodeling of the ventricle, leading to ventricular dilatation and impairment of systolic 
function, known as “tachycardia induced cardiomyopathy”. 
Stroke and thromboembolism are a major cause of mortality and morbidity associated with 
AF, and the underlying pathophysiological basis of this is a prothrombotic or 
hypercoagulable state, in association with abnormalities of blood flow (atrial stasis, for 
example) and endothelial or endocardial damage. 
The concept of primary prevention of AF with interventions targeting the development of 
substrate and modifying risk factors for AF has emerged as a result of recent experiments 
that suggested novel targets for mechanism-based therapies.  
Upstream therapy refers to the use of non-antiarrhythmic drugs that modify the atrial 
substrate- or target-specific mechanisms of AF to prevent the occurrence or recurrence of the 
arrhythmia. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor 
blockers (ARBs) may be effective in AF prevention in patients with hypertension, left 
ventricular hypertrophy, and congestive heart failure, as well as in post myocardial 
infarction patients with depressed left ventricular function8. Also statins and omega-3 
polyunsaturated fatty acids, and possibly corticosteroids. Animal experiments have 
compellingly demonstrated the protective effect of these agents against electrical and 
structural atrial remodeling in association with AF. The key targets of upstream therapy are 
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structural changes in the atria, such as fibrosis, hypertrophy, inflammation, and oxidative 
stress, but direct and indirect effects on atrial ion channels, gap junctions, and calcium 
handling are also applied. Although there have been no formal randomized controlled 
studies (RCTs) in the primary prevention setting, retrospective analyses and reports from 
the studies in which AF was a pre-specified secondary endpoint have shown a sustained 
reduction in new-onset AF with ACEIs and ARBs in patients with significant underlying 
heart disease (e.g. left ventricular dysfunction and hypertrophy), and in the incidence of AF 
after cardiac surgery in patients treated with statins. 
4. Management of AF 
AF management creates a high economic burden because of the concomitant presence of 
heart failure, coronary artery disease, hypertension, and the need for frequent 
hospitalizations. Expensive antiarrhythmic drugs and interventional procedures are other 
important factors that raise the costs of AF care. 
Four major aspects should be considered in the AF management9: 
i. Symptom control by slowing ventricular response during paroxysmal or persistent AF 
and long-term rate control in permanent AF 
ii. Cardioversion to sinus rhythm 
iii.  Maintenance of sinus rhythm after successful cardioversion 
iv.  Prevention of complications and thromboembolic events. 
Rhythm versus Rate Control 
In order to prevent the complications and symptoms of AF two main strategies exist.  
1. Rhythm control: converting the patient’s rhythm to sinus and maintaining the sinus 
rhythm. 
2. Rate control: slowing the ventricular response rate without insisting on conversion to 
sinus rhythm.  
The initial therapy after onset of AF should always include adequate antithrombotic 
treatment and control of the ventricular rate. The goal is to control the ventricular rate 
adequately whenever recurrent AF occurs. 
From a theoretical point of view, converting AF into sinus rhythm is the best option. 
Nonetheless; the most important trials reported in the existing literature thus far have 
mentioned no significant difference in terms of quality of life and other outcomes between 
the two strategies. It seems that the side effects of antiarrhythmic agents (pro-arrhythmia) in 
the long term, poor efficacy of drugs in the maintenance of sinus rhythm, and inappropriate 
discontinuation of anticoagulants in the patients who still have AF episodes can interfere 
with good results in the rhythm-control arm27.  Therefore, many experts believe that rhythm 
control with safe antiarrhythmic drugs or catheter ablation will play an important role in the 
AF management.  
The main agents for slowing ventricular response in AF are beta blockers, calcium channel 
blockers, and digoxin28. Beta-blockers and calcium channel blockers are first-line agents for 
rate control in atrial fibrillation. These drugs can be administered either intravenously or 
orally. They are effective at rest and with exertion. Caution should be exercised in patients 
with reactive airway disease who are given beta-blockers. Digoxin is sometimes used in the 
acute setting but does little to control the ventricular rate in active patients. As such, it is 
rarely used as mono therapy. The therapeutic window for digoxin as mono therapy for rate 
control is narrow and would typically yield toxic levels. Thus, there may be circumstances 
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that this drug is used as adjunctive therapy to beta-blockers or calcium channel blockers. 
Caution should be exercised in elderly patients and those with renal failure receiving 
digoxin. Digoxin is indicated in patients with heart failure and reduced LV function.  
Amiodarone has a Class IIa recommendation from the ACC/AHA/ESC for use as a rate 
controlling agent for patients who are intolerant of or unresponsive to other agents. Caution 
should be exercised in those not receiving anticoagulation as amiodarone can promote 
cardioversion. 
Criteria for rate control vary with patient age but usually involve achieving ventricular 
rates between 60 and 80 bpm at rest and between 90 and 115 bpm during moderate 
exercise.  
The potential benefits of strict (resting heart rate <80 bpm, heart rate <110 bpm during 
moderate exercise) versus lenient (resting heart rate 110 bpm) rate control were addressed in 
the RACE II  trial of  patients with permanent AF29.  The RACE II study shows that 
lenientrate control <110 bpm is not inferior to strict-rate control <80 bpm. As lenient-rate 
control is generally more convenient, requiring fewer outpatient visits and examinations, 
lenient-rate control may be adopted as a reasonable strategy in patients with permanent AF. 
In the AFFIRM study, there was no survival difference between rate-control and rhythm-
control strategies. In addition, the lower risk of adverse drug effects in the rate-control arm 
conferred some advantages in this arm. A post-hoc analysis of the AFFIRM data proved that 
there was no significant benefit in the rhythm-control group versus the rate-control group in 
patients with AF and left ventricular dysfunction30. The RACE study showed that for the 
prevention of cardiovascular mortality and morbidity in AF, rhythm control was not superior to 
rate control31. In the PIAF trial, clinical outcomes were similar between the rate-control group 
and the rhythm-control group but exercise tolerance was better in the rhythm-control arm32. 
However rhythm-control strategy is more popular than the rate-control strategy worldwide. 
Symptom control and quality of life generally are better when sinus rhythm is restored and 
maintained. Treatment analysis from the AFFIRM study42 showed that the presence of sinus 
rhythm was associated with a 47% reduction in mortality and that the use of AAD was 
associated with a significant increase in mortality of 49%, suggesting a potential benefit of 
sinus rhythm maintenance in a non-pharmacological manner.  
We hope that with the advent of new drugs for both rhythm control and anticoagulation, 
maintenance of sinus rhythm after cardioversion can be a more realistic goal. 
4.1 Cardioversion to sinus rhythm 
As a result of atrial remodelling, the longer the duration of AF the less successful is the 
cardioversion. Predictors of recurrence of AF include long standing atrial fibrillation 
(duration greater than three months), heart failure, structural heart disease, hypertension, 
increasing age (over 70), and increased left atrial size10.  
Although left atrial size is related to the duration of AF, a left atrial diameter greater than 6.5 
cm is associated with an increased risk of recurrence11. 
Cardioversion carries a 5-7% risk of thromboembolism without anticoagulation and a 1-2% 
risk after conventional anticoagulation12. Prolonged anticoagulation is not needed when 
patients present within 48 hours of onset of AF. Such patients may be safely cardioverted 
irrespective of whether heparin has been administered since presentation. Administration of 
heparin is recommended to all patients with an acute presentation, however, to allow 
flexibility in subsequent management of the arrhythmia13. 
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For stable patients, in whom the onset of AF is uncertain or greater than 48 hours, 
anticoagulation for a minimum of three weeks before cardioversion is recommended, to 
allow resolution of potential thrombi. As atrial mechanical activity may not resume 
concurrently with electrical activity, anticoagulation should be continued for at least four 
weeks after cardioversion. 
An alternative approach is to use transoesophageal echocardiography to exclude atrial 
thrombi before cardioversion is attempted. The presence of an atrial thrombus necessitates 
four to six weeks of anticoagulation before cardioversion. Even with this strategy, 
anticoagulation should be continued for at least four weeks after cardioversion. 
4.2 Pharmacological cardioversion 
Pharmacological cardioversion should be reserved for haemodynamically stable patients 
with symptoms.  In general, class I and class III antiarrhythmic agents are commonly used 
for pharmacological cardio version and maintenance of sinus rhythm. In AF episodes 
lasting less than 48 hours cardio version rate for class IC and III drugs is approximately 
60-80%14. 
In a randomised trial comparing flecainide, propafenone, and amiodarone for 
cardioversion of recent onset AF, conversion to sinus rhythm occurred in 90%, 72%, and 
64% of patients respectively15. Class IC drugs (flecainide and propafenone) should be 
avoided in patients with underlying ischaemic heart disease or impaired left ventricular 
function. Amiodarone can be used in such patients, although the time to conversion can 
range from days to weeks. 
Ibutilide is a class III antiarrhythmic agent that can convert AF to sinus rhythm more rapidly 
than can procainamide or sotalol. It has been shown that ibutilide has no significant 
advantage compared with amiodarone for the conversion of AF but severe hypotension was 
not seen with ibutilide23. For acute AF, conversion to sinus rhythm with ibutilide is about 
59%, but there is 1.7% risk of polymorphic ventricular tachycardia with this drug. As a 
result, it is advised to keep the patients receiving ibutilide under monitoring for at least 24 
hours after the infusion of this drug24. 
Dofetilide is another class III antiarrhythmic drug that can be used for maintaining sinus 
rhythm in congestive heart failure patients with AF. The DIAMOND CHF trial showed that 
it could reduce hospitalization due to heart failure. Heart failure worsening was reduced by 
25%.25Dofetilide is known to be more effective in patients with persistent AF compared with 
those with paroxysmal AF, and significant proarrhythmic adverse effects can occur even 
with close monitoring. 
Vernakalant is an atrial-selective drug treatment for atrial fibrillation which affects Na+ and 
several K+ channels in the heart. Vernakalant is most often used intravenously to stop 
recent-onset AF. A long-term oral preparation, however, is in development. Several placebo-
controlled studies have shown vernakalant to be effective in eliminating AF in about 50% of 
patients with limited side effects16, 17. In these studies, vernakalant was most effective for 
treatment of recent-onset AF, but rarely effective at all for long-standing AF. Common side 
effects of vernakalant include nausea, sneezing and dysgeusia. The FDA has recommended 
vernakalant as an intravenous treatment for recent-onset AF. 
The ‘Pill-in-the-poket’ approach may be used in selected, symptomatic patient with 
infrequent episodes of AF. Oral propafenone (450-600mg) or flecainide (200-300mg) is taken 
when symptoms of AF occur18. 
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4.3 Electrical cardioversion 
Synchronised external direct current cardioversion is a safe procedure with success rates of 
70-90%19. It is used acutely in patients who are haemodynamically compromised or 
electively as an alternative to pharmacological cardioversion. Electrical cardioversion is 
usually done under conscious sedation. If this is unsuccessful, adjunctive antiarrhythmic 
treatment with class III agents such as dofetilide, sotalol, and amiodarone can help to restore 
sinus rhythm. 
4.4 Maintenance of sinus rhythm 
Class III antiarrhythmic agents have an important role as a part of cardioversion strategy 
and maintaining sinus rhythm. Amiodarone, which is the hallmark drug in this group and 
most frequently used antiarrhythmic drug for AF treatment, is a relatively safe and effective 
drug but frequent adverse effects like thyroid dysfunction, pulmonary fibrosis, 
dermatological changes, and ophthalmic involvement have been reported with its long-term 
use20.  
Dronedarone is a benzofuran-derivate of amiodarone with the same electropharmacological 
profile36 but without side effects on the pulmonary system21. It has a shorter half-life than 
amiodarone (1 - 2 days). The recommended oral dose of dronedarone is 400 mg twice a day 
with meals. The ANDROMEDA study was terminated prematurely because of increased 
mortality due to the worsening of heart failure in the dronedarone group. Therefore, 
dronedarone is contraindicated in patients with moderate to severe heart failure26. The 
major adverse cardiac effects of dronedarone are bradycardia and QT prolongation. 
Torsades de pointes have been reported22.  Cases of rare but severe hepatic injury associated 
with use of dronedarone reported. Periodic monitoring of  liver-function test should be done  
especially in the first six months of treatment.  
Dronedarone was approved by the American FDA in March, 2009, for sinus-rhythm 
maintenance in patients with a history of atrial fibrillation/flutter with ejection fraction 
greater than 35%. 
4.5 Reduction of thromboembolic risk 
Atrial fibrillation can predispose clot formation in the left atrium and consequently ischemic 
stroke and extra cranial thromboembolism33. When stroke occurs in association with atrial 
fibrillation, patients have a greater mortality and morbidity, longer hospital stays, and 
greater disability than those without AF. If AF persists for two days, left atrium thrombosis 
could be seen in 5 - 14% of patients34. It might, subsequently, become fragmented and 
embolize to the peripheral atrial system35. 
Pooled data from trials comparing antithrombotic treatment with placebo have shown 
that warfarin reduces the risk of stroke by 62% (95% confidence interval 48% to 72%) and 
that aspirin alone reduces the risk by 22% (2% to 38%). Overall, in high risk patients, 
warfarin was better than aspirin in preventing strokes, with a relative risk reduction of 
36% (48% to 72%). The risk of major haemorrhage with warfarin was twice that with 
aspirin36. 
Anticoagulation treatment needs to be tailored individually for patients on the basis of age, 
comorbidities, and contraindications. In patients with valvular heart disease or high-risk 
individuals (according to the CHADS2 or CHA2DS2VASC  scoring), warfarin is the drug of 
choice. In low-risk conditions, aspirin can be used37. 
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Oral anticoagulation therapy with warfarin proved superior to clopidogrel plus ASA for 
prevention of vascular events in AF patients. Treatment with clopidogrel plus ASA was 
associated with bleeding risk similar to treatment with warfarin38. In the ACTIVE-A trial, AF 
patients for whom oral anticoagulation with warfarin was considered unsuitable, the 
addition of clopidogrel to ASA reduced the risk of major vascular events, especially stroke, 
and increased the risk of major hemorrhage39. 
Dabigatran is a new, potent, direct and competitive inhibitor of thrombin. Its half-life is 12 to 
17 hours, and it does not require regular monitoring.  AF patients receiving Dabigatran 110 mg 
twice daily had similar rates of stroke and systemic embolism compared with those using 
warfarin, but with lower rates of major bleeding. At a dose of 150 mg twice daily, the rate of 
stroke and systemic embolism is lower but the rate of major bleeding is similar to warfarin40. 
Apixaban, a novel factor Xa inhibitor, was tested in the AVERROES trial in patients 
unsuitable for warfarin therapy and at increased risk of stroke. The trial was stopped 
prematurely because of clear benefit in favor of apixaban, compared to aspirin41. 
4.6 Non-pharmacological therapy 
Many non-pharmacological treatments have been developed for the management of AF and 
some even afford a possible “cure”. 
4.7 Radiofrequency catheter ablation 
The past decade has witnessed radiofrequency catheter ablation of AF evolve from an 
experimental procedure to an important treatment option for many patients with AF. 
Randomized controlled trials now confirm that left atrial ablation is superior to 
antiarrhythmic drug therapy in maintaining sinus rhythm over time52- 54. 
Curative catheter ablation techniques initially attempted to mimic the lesions created by the 
surgical Maze procedure, resulting in limited success with a substantial complication rate. In 
1998, Haissaguerre et al. first demonstrated that pulmonary veins (PVs) provided focal 
firings triggering the occurrence of paroxysmal AF3. They showed that as many as 94% of 
such triggers originated from the PVs and that the elimination of these foci by 
radiofrequency (RF) energy applications in the PVs could cure the paroxysmal form of AF, 
which became the cornerstone of curative ablation of AF. However, it turned out that high 
recurrence rates of AF and late development of PV stenosis were often associated with this 
procedure43. Subsequently, a more advanced technique attempting to isolate the PV muscle 
sleeves form the left atrium evolved. 
Among various procedures to isolate the PV muscle sleeves from the LA initially employed 
by several investigators, two approaches predominated: namely, segmental ostial ablation at 
sites where localized conductions between the PV and the LA were electrophysiologically 
identified44, and anatomically guided circumferential PV ablation encircling individual 
PVs45. 
Presently, almost all centers empirically isolate all four PVs not at the ostium but outside the 
tubular portion of the PV to avoid the risk of venous stenosis and improve procedural 
efficacy. Because the PV is funnel-shaped with a large proximal end (referred to as the 
antrum), which blends into the posterior wall of the LA, isolation of the PV and the 
surrounding antral tissue has become the current goal of this procedure. 
In order to eliminate the substrate for maintaining AF, the efficiency of two additional 
adjunctive ablation strategies  of PV isolation have been described. The linear lesions are 
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made at the roof between the contralateral superior PVs (roof line) and at the isthmus 
between the mitral valve and the left inferior PV (mitral isthmus line) 46, 47. This concept 
improved the AF-free ratio from 69 to 87% in paroxysmal AF cases, although epicardial RF 
applications were required in 60% of cases to achieve the mitral isthmus block. 
Currently, the most popular method for AF substrate modification in the atrium is to apply 
RF energy and create lesions targeting the areas with complex fractionated atrial 
electrograms (CFAEs) 48. CFAEs are believed to represent slow conduction or pivot points 
where wavelets turn around at the end of arcs of functional blocks. Although the concept of 
this method is well accepted, its role in ablation strategies has not yet been fully established. 
CFAE ablation targets only the substrate to perpetuate AF, and only modest efficacy of this 
method alone for chronic AF has been reported so far49. More recently, CFAE ablation has 
been achieving a general consensus as one of the combination strategies for modifying AF 
substrates. 
Ablation treatment is successful in approximately 60% to 70% of patients that 10% to 40% of 
patients require a second ablation procedure, and that 10% to 15% still need antiarrhythmic 
drugs50.  
Success rates for catheter-based ablation are lower in patients with persistent atrial 
fibrillation than in those with paroxysmal AF. In addition, the chances of a successful 
outcome are lower in those with marked dilation of the left atrium. Oral and colleagues51 
reported 75% recurrence rate in patients with persistent AF, compared with 29% in patients 
with paroxysmal AF.  
4.8 Ablation strategy for chronic atrial fibrillation 
Multiple strategies of various procedures, including PV isolation, anatomy- or electrogram-
guided left-atrial ablation, linear ablation and thoracic vein isolation, have been developed. 
Each strategy performed alone has been shown to yield similar rates of outcome (50–70% 
success), suggesting the various co-existing targets and factors as the modifiers of the AF 
substrates. Haïssaguerre et al. developed stepwise multifaceted ablation method for chronic 
AF, which could integrate different (electrogram- and anatomy based) approaches55-57. They 
combined the approaches of PV isolation, electrogram-based ablation targeting CFAEs, 
linear ablation at the LAroof and the mitral isthmus and right atrial ablation (in some cases). 
Up to now, no single strategy is uniformly effective in patients with persistent and long-
standing persistent AF. 
4.9 Indication for catheter ablation 
Catheter ablation should generally not be the first-line therapy for atrial fibrillation. The 
primary indication for it is symptomatic atrial fibrillation that is refractory to at least one 
class 1 or class 3 antiarrhythmic drug  or the inability of a patient to tolerate these drugs. 
Another indication is in patients in whom rapid atrial fibrillation is determined to be the 
cause of tachycardia-mediated cardiomyopathy resulting in heart failure, reduced ejection 
fraction, or both. Studies have been performed in which catheter ablation was used as first-
line therapy. The expert consensus committee2 recognized this but did not fully support the 
practice. The decision to proceed with catheter ablation must be individualized on the basis 
of the risk of complications, the likely benefits, and the likelihood of success.  
Recent guidelines have class I recommendation for ablation in selected patients with 
significantly symptomatic paroxysmal AF and failed treatment with an antiarrhythmic drug 
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and have normal or mildly dilated left atria, normal or mildly reduced LV function, and no 
severe pulmonary disease, when performed in experienced centers.   
An absolute contraindication to catheter ablation is left atrial thrombus. Because of the risk 
of dislodging an existing thrombus during the procedure and causing a stroke, patients with 
persistent atrial fibrillation who are in atrial fibrillation at the time of the procedure should 
undergo trans esophageal echocardiography to screen for thrombus. 
4.10 Complications of RFA 
The most common complication associated with catheter ablation of AF is symptomatic or 
asymptomatic pulmonary vein stenosis (defined as a >70% reduction in lumen diameter), 
with an overall incidence of 1.6%. Somewhat less common are cardiac tamponade (0.7%), 
pericardial effusion (0.6%), periprocedural stroke (0.3%), and periprocedural transient 
ischemic attack (0.2%). The overall mortality rate is 0.7%58. 
It is clear that catheter ablation is more effective than AAD therapy in treating AF. However 
because of associated complication catheter ablation of AF should be considered after a 
patient has failed attempts at treatment with 1 or more AAD. 
4.11 The surgical maze procedure 
Surgeons were the first ones to treat AF effectively and reverse it to sinus rhythm. James Cox 
described a series of surgical procedures known as Cox-Maze technique. The maze procedure 
is based on the concept that a critical mass of atrial tissue is needed to allow multiple waves of 
depolarisation to spread. This surgical approach was directed to divide both right and left atria 
by a series of cuts and sutures to redirect the electrical impulse to close-end paths. This 
operation also included the exclusion of both atrial appendages and the isolation of the four 
pulmonary veins and the posterior wall of the left atrium. Nowadays, cryotherapy, bipolar 
radiofrequency, and ultrasounds are the most used energy sources. 
Although very effective, with over 91% patients maintaining sinus rhythm at 10 years, few 
surgical groups performed the Cox-Maze procedure due to the aggressiveness of it, with 
long suture lines and prolonged myocardial ischemic times59,60. Preoperative AF is 
associated with worse survival rates after valvular or coronary surgery.  Furthermore, 
patients with successful maze procedures have shown better long-term survival rates, 
higher freedom from stroke, and thromboembolic events, improved ventricular ejection 
fraction and exercise tolerance. All the above factors have expanded the indications for the 
surgical treatment of concomitant AF to most patients with coronary or valvular surgery.  
In addition, minimally invasive approaches have been described in the last five years with very 
good results for isolated paroxysmal or persistent AF. Nevertheless, prospective randomized 
trials are necessary to confirm their long-term results, compared to catheter ablation. 
4.12 Pacing for atrial fibrillation 
Atrial-based pacing, in either single- or dual-chamber mode, reduced the incidence of AF in 
several prospective multicenter studies62-67. More recently, a variety of preventive atrial 
pacing strategies, including continuous overdrive pacing, pacing in response to atrial 
premature beats, postmode switch and postexercise pacing therapies, were developed to 
reduce the burden of AF among patients with known atrial tachyarrhythmias68-73. 
However, the magnitude of AF prevention due to dedicated preventive pacing algorithms 
and the identification of responder candidates remains unclear74-76.  
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4.13 Atrioventricular node ablation  
Atrioventricular (AV) node ablation provides highly effective control of ventricular rate in 
patients with AF. Catheter ablation of AV node is a palliative but irreversible procedure and 
is therefore reasonable in patients in whom pharmacological rate control, or rhythm control 
with drugs and/or ablation therapy has failed. In such patients, AV node ablation improves 
quality of life and renders mortality similar to death rates in the general population. It is 
reasonable to assume that patients with LV systolic dysfunction may require biventricular 
pacing after AV node ablation to prevent deterioration of LV function. In patients without 
LV dysfunction, it is not established at present whether biventricular pacing is needed: some 
data suggest that biventricular pacing may be beneficial,77 while others demonstrate similar 
benefits with right ventricular pacing. 
4.14 Obliteration of the left atrial appendage 
The left atrial appendage (LAA) is considered the main site of atrial thrombogenesis.Thus, 
occlusion of the LAA may therefore be an effective way to reduce thromboembolic risk. 
Surgical closure is recommended only as an adjunctive procedure in patients undergoing 
mitral valve surgery. However devices have been developed that allows percutaneous LAA 
closure via the transeptal approach. This may be appropriate for patients who are not 
suitable for anticoagulation78. Further trials are needed to evaluate its long term safety and 
efficacy. 
4.15 Rheumatic valvular heart disease and atrial fibrillation 
AF is frequently associated with rheumatic valvular heart disease (RVHD). Valvular heart 
disease is one of risk factors for development of AF. The frequency of RVHD has decreased 
in developed but RVHD constitutes a significant burden on  healthcare in developing 
countries. 
The risk of thromboembolism in patients with RVHD and AF is high.  The stroke risk 
increases 17-fold if patients have rheumatic heart disease and AF, compared with age-
matched controls79. AF worsens hemodynamics in patients with RVHD as absent atrial kick 
and irregular ventricular rhythm lead to a fall in cardiac output. 
Results of randomized trials evaluating strategies for heart rate control or rhythm control is 
not necessarily acceptable for patients with RVHD and AF, because the majority of patients 
in these trials were non-RVHD. In patients with RVHD and AF, the maintenance of sinus 
rhythm can be expected to improve mortality and QOL. It is suggested that in RVHD and 
AF if there is no significant valvular compromise necessitating intervention and if the left 
atrium size is not more than 6.0 cms, rhythm control with amiodarone facilitated by 
electrical cardioversions should be the strategy82. If attempts to maintain SR fail over one 
year’s time, rate control measures should suffice In young patients and those with RVHD 
but no significant valve compromise, restoring and maintaining SR should be attempted. 
Patients receiving mechanical valve replacement need to continue anticoagulant therapy. It 
is unclear whether or not the maintenance of sinus rhythm influences clinical outcome for 
thromboembolism in these patients. However, the maintenance of sinus rhythm is 
important patients receiving tissue valve replacement, or balloon intervention, because they 
are likely to discontinue anticoagulant therapy.  
If AF persists, electrical and pharmacologic cardioversion are effective in restoring sinus 
rhythm, and the administration of antiarrhythmic drugs may be effective in preventing 
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AF80. However, once AF has developed in patients with RVHD, these drugs may not be 
effective in restoring sinus rhythm because of the pathological changes that develop in the 
atrium and predispose to AF.  
Surgery for AF should be utilized for patients with associated RVHD undergoing valve 
surgery. The probability of spontaneous conversion to SR after isolated mitral valve surgery 
is less than 10%. Patients who return to SR after mitral valve replacement or repair 
demonstrate better survival and freedom from adverse events.  
After the success of the Cox maze III procedure in treating AF, several surgeons began to 
add the maze procedure as an adjunct to mitral valve surgery to treat both problems81. 
Successful restoration of SR has been achieved in 70-96% of patients. 
5. Conclusion 
Recent developments in pharmacological and non-pharmacological therapy have opened a 
new horizon in management of AF.  Cure of AF has, however become a realistic goal albeit 
in limited number of patients and will remain a challenge for years to come. 
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